Combination Chemotherapy with Methotrexate, Etoposide, and Actinomycin D for High-Risk Gestational Trophoblastic Tumors

This publication has 12 references indexed in Scilit:

• Comparison of Chemotherapies with Methotrexate, VP-16 and Actinomycin-D in Low-Risk Gestational Trophoblastic Disease
  Gynecologic and Obstetric Investigation, 1998
• The Management of Gestational Trophoblastic Tumors with Etoposide, Methotrexate, and Actinomycin D
  Gynecologic Oncology, 1997
• Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy
  American Journal of Obstetrics and Gynecology, 1996
• Alternating weekly chemotherapy with etoposide-methotrexatedactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease
  International Journal of Gynecology & Obstetrics, 1994
• 5-Day Methotrexate for Women with Metastatic Gestational Trophoblastic Disease
  Gynecologic Oncology, 1994
• EMACO in High Risk Gestational Trophoblast Disease ‐ The Australian Experience
  Australian and New Zealand Journal of Obstetrics and Gynaecology, 1994
• Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989
  BJOG: An International Journal of Obstetrics and Gynaecology, 1991
• EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT)
  Gynecologic Oncology, 1988
• Developments in chemotherapy for medium‐ and high‐risk patients with gestational trophoblastic tumours (1979–1984)
  BJOG: An International Journal of Obstetrics and Gynaecology, 1986
• Anti-tumour activity of the epipodophyllin derivative VP16–213 (etoposide: NSC-141540) in gestational choriocarcinoma
  Published by Elsevier ,1980